著者

結核療法研究協議会

出版者

一般社団法人 日本結核病学会

雑誌

結核 (ISSN:00229776)

巻号頁・発行日

vol.49, no.7, pp.207-215, 1974

---

The efficacy and the side-effects of Tuberactinomycin-N (TUM-N) in the retreatment of pulmonary tuberculosis were studied and compaired with those of Viomycin (VM). The drug resistance of tubercle bacilli isolated from the patients during treatment was also studied for TUM-N and VM.<BR>TUM-N i s a new antituberculous drug isolated from the culture filtrate of Streptomyces. griseoverticillatus var. tuberacticus (N 6-130 strain). This drug shows almost the same activity as VM for tubercle bacilli and one way cross resistance for kanamycin.<BR>In this study, two following regimens were allocated ran d o mly for retreated patients.<BR>(1) TUM-N group: TUM-N was injected 1 g daily for the first three months, thereafter injected twice weekly. (45 cases)<BR>(2) VM group: VM wa s injected 1 g three times a week. (38 cases)<BR>If there are previously unused drug, they were combined with TUM-N or VM. The results were summarized as follows;<BR>(1) TUM-N group showed slmo s t the same negative conversion rate on culture as VM, group.<BR>(2) All of the cases treated with TUM-N combined with two previously unused drugs. showed 100% negative conversion rate on culture at 6 months.<BR>(3) The incidence of side-effects was lower in TU M -N group compared with VM group. The auditory disturbance was 2.2% in TUM-N group and 5.7% in VM group. The renal, disturhance defined by the raise of BUN level over 20 mg/d<I>l</I> was observed in 23.7% among -VM group while it was 10.9% in TUM-N group. The dropped-out cases due to side-effects -were 3 (6.5%) among 46 cases of TUM-N group and 8(21.2%) among 38 cases of VM group.<BR>(4) The criterion of drug resistance of TUM-N was examined and it was concluded that the growth on 1% Ogawa's media containing 100 mcg/m<I>l</I> TUM-N should be considered as resistant.